Should the first-trimester aneuploidy screen be maternal age adjusted? Screening by absolute risk versus risk adjusted to maternal age

Prenatal Diagnosis

Volumn 29, Issue 3, 2009, Pages 245-247

  Gebb, Juliana ^a   Dar, Pe'er ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Advanced maternal age; First trimester screen; Foetal imaging; maternal serum screening; Foetal ultrasound; Genetic counselling; Nuchal translucency

Indexed keywords

ADULT; ANEUPLOIDY; ARTICLE; CHROMOSOME ABERRATION; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; FETUS; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL SERUM; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; STUDENT T TEST;

ADULT; ANEUPLOIDY; COHORT STUDIES; FEMALE; GENETIC COUNSELING; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RETROSPECTIVE STUDIES; RISK;

EID: 61449121123     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2157     Document Type: Article

References (9)

1. ACOG Committee on Practice Bulletins. 2007. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 109(1): 217-227.
2. Centini G, Rosignoli L, Scarinci R, et al. 2005. Re-evaluation of risk for down syndrome by means of the combined test in pregnant women of 35 years or more. Prenat Diagn 25(2): 133-136.
3. Kuppermann M, Goldberg JD, Nease RF Jr, Washington AE. 1999. Who should be Offered Prenatal Diagnosis? The 35-year-old Question. Am J Public Health 89(2): 160-163.
4. Merkatz IR, Nitowsky HM, Macri JN, Johnson WE. 1984. An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol 148(7): 886-894.
5. Resta RG. 2005. Changing demographics of advanced maternal age (AMA) and the impact on the predicted incidence of Down syndrome in the United States: Implications for prenatal screening and genetic counseling. Am J Med Genet A 133A(1): 31-36.
6. Schmidt P, Rom J, Maul H, Vaske B, Hillemanns P, Scharf A. 2007. Advanced First Trimester Screening (AFS): An improved test strategy for the individual risk assessment of fetal aneuploidies and malformations. Arch Gynecol Obstet 276: 159-166.
7. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH, Fetal Medicine Foundation First Trimester Screening Group. 1998. UK multicentre project on assessment ofriskoftrisomy21 bymaternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 352(9125): 343-346.
8. Wapner R, Thom E, Simpson JL, et al, First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. 2003. First-trimester screening for trisomies 21 and 18.c. N Engl J Med 349(15): 1405-1413.
9. Zoppi MA, Ibba RM, Putzolu M, Floris M, Monni G. 2001. Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older. Obstet Gynecol 97(6): 916-920.